No Cover Image

Journal article 621 views 514 downloads

A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease / Manon F. Pritchard, Lydia C. Powell, Georgina Menzies, Paul Lewis, Karl Hawkins, Chris Wright, Iolo Doull, Timothy R. Walsh, Edvar Onsøyen, Arne Dessen, Rolf Myrvold, Philip D. Rye, Astrid H. Myrset, Howard N. E. Stevens, Lee A. Hodges, Gordon MacGregor, James B. Neilly, Katja E. Hill, David W. Thomas, Christopher Wright

Molecular Pharmaceutics, Volume: 13, Issue: 3, Pages: 863 - 872

Swansea University Authors: Georgina Menzies, Paul Lewis, Karl Hawkins, Christopher Wright

Abstract

The host- and bacteria-derived extracellular polysaccharide coating of the lung is a considerable challenge in chronic respiratory disease and is a powerful barrier to effective drug delivery. A low molecular weight 12–15-mer alginate oligosaccharide (OligoG CF-5/20), derived from plant biopolymers,...

Full description

Published in: Molecular Pharmaceutics
ISSN: 1543-8384 1543-8392
Published: 2016
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa26822
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: The host- and bacteria-derived extracellular polysaccharide coating of the lung is a considerable challenge in chronic respiratory disease and is a powerful barrier to effective drug delivery. A low molecular weight 12–15-mer alginate oligosaccharide (OligoG CF-5/20), derived from plant biopolymers, was shown to modulate the polyanionic components of this coating. Molecular modeling and Fourier transform infrared spectroscopy demonstrated binding between OligoG CF-5/20 and respiratory mucins. Ex vivo studies showed binding induced alterations in mucin surface charge and porosity of the three-dimensional mucin networks in cystic fibrosis (CF) sputum. Studies in Humans showed that OligoG CF-5/20 is safe for inhalation in CF patients with effective lung deposition and modifies the viscoelasticity of CF-sputum. OligoG CF-5/20 is the first inhaled polymer therapy, represents a novel mechanism of action and therapeutic approach for the treatment of chronic respiratory disease, and is currently in Phase IIb clinical trials for the treatment of CF.
Item Description: ACS AuthorChoice - This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
Keywords: mucin, sputum, polymer therapy, alginate, cystic fibrosis, viscoelasticity, safety
College: College of Engineering
Issue: 3
Start Page: 863
End Page: 872